322 related articles for article (PubMed ID: 25393798)
41. Alectinib Approved for ALK+ Lung Cancer.
Cancer Discov; 2016 Feb; 6(2):115. PubMed ID: 26739884
[TBL] [Abstract][Full Text] [Related]
42. Crizotinib: an anaplastic lymphoma kinase inhibitor.
Gadgeel SM; Bepler G
Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
[TBL] [Abstract][Full Text] [Related]
43. Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib.
Taima K; Tanaka H; Tanaka Y; Itoga M; Takanashi S; Tasaka S
Intern Med; 2017 Sep; 56(17):2321-2324. PubMed ID: 28794366
[TBL] [Abstract][Full Text] [Related]
44. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
[TBL] [Abstract][Full Text] [Related]
45. FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.
Larkins E; Blumenthal GM; Chen H; He K; Agarwal R; Gieser G; Stephens O; Zahalka E; Ringgold K; Helms W; Shord S; Yu J; Zhao H; Davis G; McKee AE; Keegan P; Pazdur R
Clin Cancer Res; 2016 Nov; 22(21):5171-5176. PubMed ID: 27413075
[TBL] [Abstract][Full Text] [Related]
46. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
Gainor JF; Sherman CA; Willoughby K; Logan J; Kennedy E; Brastianos PK; Chi AS; Shaw AT
J Thorac Oncol; 2015 Feb; 10(2):232-6. PubMed ID: 25526238
[TBL] [Abstract][Full Text] [Related]
47. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.
Kim YH; Ozasa H; Nagai H; Sakamori Y; Yoshida H; Yagi Y; Nakaoku T; Mishima M
J Thorac Oncol; 2013 Sep; 8(9):e85-6. PubMed ID: 23945393
[No Abstract] [Full Text] [Related]
48. ALK, lung cancer, and personalized therapy: portent of the future?
Garber K
J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
[No Abstract] [Full Text] [Related]
49. Treatment of ALK-positive non-small cell lung cancer.
Bang YJ
Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic management of ALK+ nonsmall cell lung cancer patients.
Duchemann B; Friboulet L; Besse B
Eur Respir J; 2015 Jul; 46(1):230-42. PubMed ID: 25929953
[TBL] [Abstract][Full Text] [Related]
51. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
52. ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
Girard N; Audigier-Valette C; Cortot AB; Mennecier B; Debieuvre D; Planchard D; Zalcman G; Moro-Sibilot D; Cadranel J; Barlési F
Expert Rev Anticancer Ther; 2015 Feb; 15(2):225-33. PubMed ID: 25413260
[TBL] [Abstract][Full Text] [Related]
53. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
Zhu V; Ou SH
Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
[TBL] [Abstract][Full Text] [Related]
54. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
55. Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer.
Koizumi T; Fukushima T; Tatai T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S
Lung Cancer; 2015 Apr; 88(1):112-3. PubMed ID: 25678258
[TBL] [Abstract][Full Text] [Related]
56. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
[TBL] [Abstract][Full Text] [Related]
57. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
58. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
Dikopf A; Wood K; Salgia R
Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
[TBL] [Abstract][Full Text] [Related]
59. [Personalized treatment in non-small cell lung cancer].
Campos-Parra AD; Cruz-Rico G; Arrieta O
Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
[No Abstract] [Full Text] [Related]
60. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
